Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and Immunogenicity of PMG1016 in Healthy Volunteers
NCT07615985Phase 1Recruiting
- Sponsor
- Pulmongene (Hong Kong) Co., Ltd.
- Start
- May 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PMG1016 in chronic kidney disease (CKD) (4 cohorts), sponsored by Pulmongene (Hong Kong) Co., Ltd. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 14 more. Started May 2026; status: recruiting.
02
Drugs
PMG1016
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07615985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615985.